The treatment of male subfertility with kallikrein.

Abstract

In a controlled double blind trial the effectiveness and tolerability of Kallikrein in patients suffering from astheno-oligozoospermia was examined in comparison to placebo. 30 patients with astheno-oligozoospermia of idiopathic origin entered the study; they were subdivided into two homogeneous groups of 15 patients each. Group A was treated with 600 K.U. daily for 3 months, group B received placebo tablets. In the Kallikrein group all parameters improved, as sperm motility, volume of semen, sperm concentration, total sperm value, and rate of normal spermatozoa. No changes of endocrinological findings were observed. Three pregnancies occurred in this group. No conceptions were observed in the wives of those patients treated with placebo (group B). Tolerability was very good in all patients.

• Authors: P L Izzo, D Canale, B Bianchi, P Meschini, G Esposito, G F Menchini Fabris, R Fasani, H Ohnmeiss
• Journal: Andrologia (Andrologia) 1984 Mar-Apr Vol. 16 Issue 2 Pg. 156-61 ISSN: 0303-4569 [Print] Germany
• PMID: 6377970 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Kallikreins

Topics

• Clinical Trials as Topic
• Humans
• Kallikreins (therapeutic use)
• Male
• Oligospermia (drug therapy)
• Sperm Count
• Sperm Motility (drug effects)